Severe Combined Immunodeficiency (SCID)
Severe combined immunodeficiency (SCID) is a primary immunodeficiency disorder that involves combined humoral and cellular immunity deficiencies. It is caused by mutations in any one of many different genes (eg, for autosomal recessive forms, Janus kinase 3 [JAK3], protein tyrosine phosphatase, receptor type, C [PTPRC, or CD45], recombination activating genes 1 [RAG1] and 2 [RAG2]). There are various forms of SCID that are autosomal recessive defects, so for the infant to be affected with SCID, the same gene must be mutated on both chromosomes.
There are 4 different abnormal lymphocyte phenotypes:
In most forms of SCID, T cells are absent (T-); the number of B cells and/or natural killer (NK) cells may be low or none (B-; NK-) or high or normal (B+; NK+), depending on the form of SCID. However, B cells, even when normal in number, cannot function because T cells are absent. Natural killer cell function is usually impaired.
The most common form of SCID is X-linked. It affects the interleukin (IL)-2 receptor common gamma chain (a component of at least 6 cytokine receptors) and thus causes severe disease; phenotype is T- B+ NK-. It results from a mutation in the IL-2 receptor gamma gene (IL-2RG).
The 2nd most common form results from adenosine deaminase (ADA) deficiency, which leads to apoptosis of precursors for B, T, and NK cells; phenotype is T- B- NK-.
The next most common form results from IL-7 receptor alpha-chain deficiency; phenotype is T- B+ NK+.
Mutations in recombination activating gene 1-2 (RAG1 or RAG2) represent a T-B-NK+ SCID phenotype.
Omenn syndrome is another T-B-NK+ SCID phenotype. It typically is the result of one defective RAG allele and therefore is commonly referred to as atypical SCID, or leaky SCID. It is an autosomal recessive form of SCID. Frequently the levels of IgA, IgG, and IgM are low while there is elevated IgE and eosinophilia. These patients usually have a varying degree of lymphopenia with low numbers of T and B cells and present with inflammation and lymphadenopathy.
By age 6 months, most infants with SCID develop candidiasis, persistent viral infections, Pneumocystis jirovecii pneumonia, and diarrhea, leading to failure to thrive. Some have graft-vs-host disease due to maternal lymphocytes or blood transfusions. Other infants present at age 6 to 12 months. Patients with Omenn syndrome may develop exfoliative dermatitis, erythroderma, desquamation, alopecia, chronic diarrhea, failure to thrive, lymphadenopathy, eosinophilia, hepatosplenomegaly, and elevated serum IgE levels. ADA deficiency may cause bone abnormalities. In all forms, the thymus is extremely small, and lymphoid tissue may be decreased or absent.
All forms of SCID are fatal during infancy unless they are diagnosed and treated early.
Screening all neonates using the TREC test is often recommended and is done routinely in many US states.
Severe combined immunodeficiency is suspected in infants with a history of persistent infections or other characteristic manifestations. Complete blood count, including absolute WBC count and differential, is done; immunoglobulin levels are measured. Responses to mitogens and to standard vaccine antigens are determined to evaluate WBC and antibody function.
The disorder is diagnosed in patients with the following:
Other tests are done to determine the type of SCID; they include flow cytometry to determine T, B, and natural killer cell counts. ADA and purine nucleoside phosphorylase levels in WBCs, red blood cells, and fibroblasts are measured. X-inactivation tests may be done to determine whether SCID is X-linked. To help determine severity and prognosis, clinicians often test patients for common mutations that are characteristic of SCID (eg, IL-2RG, RAG1 and RAG2, JAK3, Artemis [DCLRE1C]).
Genetic testing of relatives is not recommended, except for siblings born after the diagnosis is made.
Patients with severe combined immunodeficiency must be kept in reverse isolation.
Treatment with immune globulin replacement therapy, antibiotics (including P. jirovecii prophylaxis), and antifungals can help prevent infections but is not curative.
In 90 to 100% of infants with SCID or its variants, hematopoietic stem cell transplantation from an HLA-identical, mixed leukocyte culture–matched sibling restores immunity. When an HLA-identical sibling is not available, haploidentical hematopoietic stem cells from a parent that is rigorously depleted of T cells can be used. If SCID is diagnosed by age 3 months, the survival rate after transplantation with either type of hematopoietic stem cells is 96%. Pretransplantation chemotherapy is unnecessary because patients do not have T cells and therefore cannot reject a graft.
Patients with ADA deficiency who do not receive a bone marrow graft may be treated with injections of polyethylene glycol–modified bovine ADA once or twice a week.
Gene therapy has been successful in ADA-deficient SCID, and no posttreatment leukemias or lymphomas have been reported. Gene therapy has also been successful in X-linked SCID but has caused T-cell leukemias, precluding its use. Gene therapy for other forms of SCID is under study.
Suspect severe combined immunodeficiency (SCID) if infants have recurrent infections, graft-vs-host disease, or exfoliative dermatitis.
The diagnosis is confirmed if patients have lymphopenia, deficient numbers of T cells, and no lymphocyte proliferative responses to mitogens.
Determine T, B, and natural killer cell counts to identify the type of SCID.
Give prophylactic immune globulin and antimicrobials.
Do hematopoietic stem cell transplantation early whenever possible.
If patients with ADA-deficient SCID do not receive a bone marrow graft, use ADA replacement and sometimes gene therapy.
Drugs Mentioned In This Article
|Drug Name||Select Trade|